Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants

Only low antibody levels were obtained from vaccinating human volunteers with singlechain peptide from the Plasmodium falciparum circumsporozoite protein (PfCSP). This resulted in modest protection against sporozoite challenge. In addition, HLA restriction limits the probability of synthesis of a va...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 1998-01, Vol.16 (2), p.305-312
Main Authors: Le, Thong P., Preston Church, L.W., Corradin, Giampietro, Hunter, Robert L., Charoenvit, Yupin, Wang, Ruobing, de la Vega, Patricia, Sacci, John, Ripley Ballou, W., Kolodny, Nelly, Kitov, Svetlana, Glenn, Gregory M., Richards, Roberta L., Alving, Carl R., Hoffman, Stephen L.
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic
Animals
Antigens, Protozoan - immunology
Apicomplexa - immunology
Biological and medical sciences
circumsporozoite protein
Female
Fundamental and applied biological sciences. Psychology
Mice
Mice, Inbred BALB C
multiple antigen peptide
Plasmodium falciparum - immunology
Plasmodium falciparum vaccine
Protozoa
Protozoan Proteins - immunology
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Only low antibody levels were obtained from vaccinating human volunteers with singlechain peptide from the Plasmodium falciparum circumsporozoite protein (PfCSP). This resulted in modest protection against sporozoite challenge. In addition, HLA restriction limits the probability of synthesis of a vaccine effective for a diverse population. We report immunization studies with a multiple antigen peptide (MAP) system consisting of multiple copies of a B-cell epitope from the central repeat region of the PfCSP in combination with a universal T-cell epitope, the P2P30 portion of tetanus toxin. This MAP4(NANP) 6P2P30 vaccine was highly immunogenic in four different strains of mice when used with various safe and nontoxic adjuvants. When this MAP vaccine was encapsulated in liposomes with lipid A and adsorbed to aluminum hydroxide and given three times at 4-week intervals, the resultant antibody prevented 100% of sporozoites from invading and developing into liver stage infection. This high degree of immunogenicity of MAP4(NANP) 6P2P30 vaccine formulated in liposomes, lipid A and aluminum hydroxide provides the foundation for consideration of human trials with this formulation.
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(97)00165-5